Market revenue in 2023 | USD 184.0 million |
Market revenue in 2030 | USD 297.2 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Attenuated vaccine |
Fastest growing segment | DNA Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 30.38% in 2023. Horizon Databook has segmented the Japan vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The vaccine contract manufacturing market in Japan is highly competitive, with several local and international players operating in the market. Some of the major players in the market include Fujifilm Diosynth Biotechnologies, AGC Biologics, JCR Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Company Limited.
Fujifilm Diosynth Biotechnologies is a key player in the market, offering a wide range of services, including process development, cGMP manufacturing, and analytical services for vaccines & biologics. The company has state-of-the-art facilities in Japan, the UK, and the U.S.
Several key players have expanded their contract manufacturing offerings in Japan to increase their market foothold. For instance, in December 2023, Ajinomoto Co., Inc. has recently acquired all the shares of Forge Biologics Holdings, LLC.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Japan vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account